Verge to receive up to $42M in upfront and near-term payments, with future cumulative milestones worth up to $840M The collaboration is the second with a leading global pharmaceutical company and shows the unique scalability of the CONVERGE™ platform for technology-enabled drug discovery SOUTH SAN FRANCISCO, Calif., Sept.

预计将获得高达4200万美元的前期和近期支付，未来累计里程碑价值高达8.4亿美元。这项合作是全球领先制药公司的第二项合作，展示了CONVERGE的独特可扩展性™ 技术支持药物发现平台南旧金山，加利福尼亚州，9月。

08, 2023 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company transforming drug discovery using artificial intelligence (AI) and patient tissue data, today announced a multi-target collaboration with Alexion, AstraZeneca Rare Disease ('Alexion') to identify novel drug targets for rare neurodegenerative and neuromuscular diseases.

082023（GLOBE NEWSWIRE）-Verge Genomics，一家临床阶段生物技术公司，利用人工智能（AI）和患者组织数据改变药物发现，今天宣布与Alexion，AstraZeneca Rare Disease（'Alexion'）进行多目标合作确定罕见神经退行性疾病和神经肌肉疾病的新药靶点。

Under the terms of the four-year agreement, Verge will receive up to $42 million, consisting of upfront fee, equity, and near-term payments, with a potential deal value of $840 million plus potential downstream royalties. “By leveraging Verge’s AI-enabled platform in combination with data from patient tissue samples, we see potential in helping researchers more efficiently identify and validate therapeutic targets for rare diseases,” said Seng H.

根据四年协议条款，Verge将获得高达4200万美元，包括前期费用，股权和近期支付，潜在交易价值为8.4亿美元，以及潜在的下游特许权使用费。Seng H说：“通过利用Verge的AI平台与患者组织样本的数据相结合，我们发现有可能帮助研究人员更有效地识别和验证罕见疾病的治疗目标。”。

Cheng, Senior Vice President, Head of Research and Product Development, Alexion. “This collaboration will contribute to Alexion’s science-led innovation and may help accelerate our efforts to transform the discovery and development of new medicines for patients with rare disease.” The collaboration, which is Verge’s second with a leading global pharmaceutical company, will leverage CONVERGE™, a full-stack platform that combines highly predictive human tissue datasets with machine learning to find new targets with a higher probability of clinical success.

Cheng，Alexion研究与产品开发总监高级副总裁。“这项合作将有助于Alexion以科学为主导的创新，并可能有助于加速我们努力改变罕见病患者新药的发现和开发。”这项合作与全球领先的制药公司Verge仅次于Verge，将利用CONVERGE™, 一个完整的堆栈平台，将高度预测的人体组织数据集与机器学习相结合，以找到具有更高临床成功概率的新目标。

Instead of starting with cell or animal models, Verge’s drug discovery platform is based on a proprietary .

Verge的药物发现平台不是从细胞或动物模型开始，而是基于专有的。